Meenesh R Juvekar, Gauri Kapre Vaidya, Aniruddha Majumder, Amod D Pendharkar, Anthony Irudhayarajan, Avijit Kundu, D Ramesh, J Dheeraj Kumar, B Jagannatha, Joseph Mathew, Mahesh P Nikam, Madhuri Mehta, Neeraj Chawla, Priti Hajare, P G Chandre Gowda, P V L N Murthy, Suma Moni Mathew, Makarand V Damle, Chandra Kant, Arun B Nair, Ashok Jaiswal, Ravi T Mehta
BACKGROUND: Allergic rhinitis (AR) has shown an increasing prevalence leading to a considerable medical and social burden. Nasal congestion is the cardinal symptom of AR, and the upper respiratory tract is most affected by this long-lasting ailment. Intranasal corticosteroids alleviate nasal congestion, along with other symptoms of AR, but their effect is not evident immediately. Oxymetazoline has a rapid onset of action, but its use should be limited to 3-5 days. OBJECTIVE: The study aimed to evaluate the safety and effectiveness of the fixed-dose combination nasal spray containing fluticasone furoate and oxymetazoline hydrochloride (FF + OXY) 27...
January 9, 2024: Clinical Drug Investigation